Citation Impact
Citing Papers
Sexual Function After Breast Cancer
2010
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
2013
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Breast cancer
2016 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
2012 Standout
Targeted Therapy for Breast Cancer
2013
The odyssey of marine pharmaceuticals: a current pipeline perspective
2010
Natural products: A continuing source of novel drug leads
2013 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Marine natural products
1990 Standout
Nomograms in oncology: more than meets the eye
2015 Standout
Drug development from marine natural products
2008 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Natural product synthesis in the age of scalability
2013
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
2016 StandoutNobel
Different strategies to overcome multidrug resistance in cancer
2013
Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score−matched Surveillance, Epidemiology, and End Results analysis
2013
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
2012
From the Sea to Anticancer Therapy
2011
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
2011
How were new medicines discovered?
2011 Standout
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
2011
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Interactions of Halichondrin B and Eribulin with Tubulin
2011
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
2013
Body Image in Younger Breast Cancer Survivors
2015 Standout
Gallbladder cancer: epidemiology and outcome
2014 Standout
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
2013
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer
2012
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer
2014
Marine natural products
2015 Standout
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
Neue Ziele für die Photopharmakologie
2016 StandoutNobel
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Nomogram for Predicting the Benefit of Adjuvant Chemoradiotherapy for Resected Gallbladder Cancer
2011
Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts
2013
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
2018
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2015
A Historical Overview of Natural Products in Drug Discovery
2012 Standout
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Finding chemo: the search for marine-based pharmaceutical drugs active against cancer
2013
Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy
2011
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
2009
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
2013
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of Ragene Rivera being referenced
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
2012
Post-Operative Adjuvant Radiochemotherapy in the Treatment of Gallbladder Cancer
2005
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
2009
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2009
Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
2007
Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
2010
Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer
2007
Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).
2010